|
1
|
Hofmann HS, Neef H, Krohe K, Andreev P and
Silber RE: Prognostic factors and survival after pulmonary
resection of metastatic renal cell carcinoma. Eur Urol. 48:77–82.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Levy DA, Slaton JW, Swanson DA and Dinney
CP: Stage specific guidelines for surveillance after radical
nephrectomy for local renal cell carcinoma. J Urol. 159:1163–1167.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ljungberg B, Alamdari FI, Rasmuson T and
Roos G: Follow-up guidelines for nonmetastatic renal cell carcinoma
based on the occurrence of metastases after radical nephrectomy.
BJU Int. 84:405–411. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pyrhönen S, Salminen E, Ruutu M, et al:
Prospective randomized trial of interferon alfa-2a plus vinblastine
versus vinblastine alone in patients with advanced renal cell
cancer. J Clin Oncol. 17:2859–2867. 1999.PubMed/NCBI
|
|
5
|
Motzer RJ, Michaelson MD, Redman BG, et
al: Activity of SU11248, a multitargeted inhibitor of vascular
endothelial growth factor receptor and platelet-derived growth
factor receptor, in patients with metastatic renal cell carcinoma.
J Clin Oncol. 24:16–24. 2006. View Article : Google Scholar
|
|
6
|
Escudier B, Eisen T, Stadler WM, et al:
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J
Med. 356:125–134. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shimizu K, Uemura H, Yoshikawa M, et al:
Induction of antigen-specific cellular immunity by vaccination with
peptides from MN/CA IX in renal cell carcinoma. Oncol Rep.
10:1307–1311. 2003.PubMed/NCBI
|
|
8
|
Sato E, Torigoe T, Hirohashi Y, et al:
Identification of an immunogenic CTL epitope of HIFPH3 for
immunotherapy of renal cell carcinoma. Clin Cancer Res.
14:6916–6923. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Boon T and Old LJ: Cancer tumor antigens.
Curr Opin Immunol. 9:681–683. 1997. View Article : Google Scholar
|
|
10
|
Scanlan MJ, Gure AO, Jungbluth AA, Old LJ
and Chen YT: Cancer/testis antigens: an expanding family of targets
for cancer immunotherapy. Immunol Rev. 188:22–32. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Uyttenhove C, Godfraind C, Lethé B, et al:
The expression of mouse gene P1A in testis does not prevent safe
induction of cytolytic T cells against a P1A-encoded tumor antigen.
Int J Cancer. 70:349–356. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jungbluth AA, Chen YT, Stockert E, et al:
Immunohistochemical analysis of NY-ESO-1 antigen expression in
normal and malignant human tissues. Int J Cancer. 92:856–860. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
De Plaen E, Arden K, Traversari C, et al:
Structure, chromosomal localization, and expression of 12 genes of
the MAGE family. Immunogenetics. 40:360–369. 1994.PubMed/NCBI
|
|
14
|
Chomez P, De Backer O, Bertrand M, De
Plaen E, Boon T and Lucas S: An overview of the MAGE gene family
with the identification of all human members of the family. Cancer
Res. 61:5544–5551. 2001.PubMed/NCBI
|
|
15
|
Chen YT, Scanlan MJ, Sahin U, et al: A
testicular antigen aberrantly expressed in human cancers detected
by autologous antibody screening. Proc Natl Acad Sci USA.
94:1914–1918. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen YT, Chiu R, Lee P, et al: Chromosome
X-encoded cancer/testis antigens show distinctive expression
patterns in developing gonads and in testicular seminoma. Hum
Reprod. 26:3232–3243. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Aoki M, Ueda S, Nishikawa H, et al:
Antibody responses against NY-ESO-1 and HER2 antigens in patients
vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1
and CHP-HER2 with OK-432. Vaccine. 27:6854–6861. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shirakura Y, Mizuno Y, Wang L, et al:
T-cell receptor gene therapy targeting melanoma-associated
antigen-A4 inhibits human tumor growth in non-obese
diabetic/SCID/γcnull mice. Cancer Sci. 103:17–25. 2012.PubMed/NCBI
|
|
19
|
Yamanaka K, Miyake H, Hara I, Gohji K,
Arakawa S and Kamidono S: Expression of MAGE genes in renal cell
carcinoma. Int J Mol Med. 2:57–60. 1998.PubMed/NCBI
|
|
20
|
Neumann E, Engelsberg A, Decker J, et al:
Heterogeneous expression of the tumor-associated antigens RAGE-1,
PRAME, and glycoprotein 75 in human renal cell carcinoma:
candidates for T-cell-based immunotherapies? Cancer Res.
58:4090–4095. 1998.
|
|
21
|
Jungbluth AA, Busam KJ, Kolb D, et al:
Expression of MAGE-antigens in normal tissues and cancer. Int J
Cancer. 85:460–465. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Coral S, Sigalotti L, Altomonte M, et al:
5-aza-2′-deoxycytidine-induced expression of functional cancer
testis antigens in human renal cell carcinoma: immunotherapeutic
implications. Clin Cancer Res. 8:2690–2695. 2002.
|
|
23
|
Kienstra MA, Neel HB, Strome SE and Roche
P: Identification of NY-ESO-1, MAGE-1, and MAGE-3 in head and neck
squamous cell carcinoma. Head Neck. 25:457–463. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Scanlan MJ, Altorki NK, Gure AO, et al:
Expression of cancer-testis antigens in lung cancer: definition of
bromodomain testis-specific gene (BRDT) as a new CT gene, CT9.
Cancer Lett. 150:155–164. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Figueiredo DL, Mamede RC, Spagnoli GC, et
al: High expression of cancer testis antigens MAGE-A, MAGE-C1/CT7,
MAGE-C2/CT10, NY-ESO-1, and gage in advanced squamous cell
carcinoma of the larynx. Head Neck. 33:702–707. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pastorcic-Grgic M, Sarcevic B, Dosen D,
Juretic A, Spagnoli GC and Grgic M: Prognostic value of MAGE-A and
NY-ESO-1 expression in pharyngeal cancer. Head Neck. 32:1178–1184.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cuffel C, Rivals JP, Zaugg Y, et al:
Pattern and clinical significance of cancer-testis gene expression
in head and neck squamous cell carcinoma. Int J Cancer.
128:2625–2634. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Atanackovic D, Blum I, Cao Y, et al:
Expression of cancer-testis antigens as possible targets for
antigen-specific immunotherapy in head and neck squamous cell
carcinoma. Cancer Biol Ther. 5:1218–1225. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
De Smet C, Lurquin C, Lethe B, Martelange
V and Boon T: DNA methylation is the primary silencing mechanism
for a set of germ line- and tumor-specific genes with a CpG-rich
promoter. Mol Cell Biol. 19:7327–7335. 1999.PubMed/NCBI
|
|
30
|
Demirovic A, Dzombeta T, Tomas D, et al:
Immunohistochemical expression of tumor antigens MAGE-A3/4 and
NY-ESO-1 in renal oncocytoma and chromophobe renal cell carcinoma.
Pathol Res Pract. 206:695–699. 2010. View Article : Google Scholar : PubMed/NCBI
|
